Meiji Yasuda Life Insurance Co bought a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 5,000 shares of the medical instruments supplier’s stock, valued at approximately $976,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Almanack Investment Partners LLC. purchased a new stake in Becton, Dickinson and during the first quarter worth about $105,000. Parkside Financial Bank & Trust lifted its position in shares of Becton, Dickinson and by 1.4% during the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 9 shares in the last quarter. QCI Asset Management Inc. NY boosted its stake in shares of Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 60 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares during the period. Finally, Financial Architects Inc boosted its stake in shares of Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the period. 87.12% of the stock is owned by institutional investors.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 193.73 on Wednesday. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The firm has a 50-day moving average price of $197.55 and a 200-day moving average price of $192.30. The firm has a market capitalization of $44.09 billion, a PE ratio of 56.10 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company’s revenue was down 5.1% on a year-over-year basis. During the same period last year, the business posted $2.35 EPS. On average, analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 8th were issued a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a yield of 1.51%. The ex-dividend date of this dividend was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

WARNING: “Meiji Yasuda Life Insurance Co Takes $976,000 Position in Becton, Dickinson and Company (BDX)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/04/meiji-yasuda-life-insurance-co-takes-976000-position-in-becton-dickinson-and-company-bdx.html.

A number of research analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Becton, Dickinson and in a report on Friday, September 22nd. They issued an “outperform” rating and a $225.00 price objective for the company. Piper Jaffray Companies reaffirmed a “buy” rating and set a $213.00 target price on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Cowen and Company reiterated a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Barclays PLC reissued an “equal weight” rating and issued a $210.00 price target (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and has an average rating of “Buy” and a consensus target price of $200.93.

In other news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the sale, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. In the last 90 days, insiders sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.